# Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes

> **NCT05597202** · PHASE4 · UNKNOWN · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 22 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Semaglutide, 2.0 mg/mL

## Key facts

- **NCT ID:** NCT05597202
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-01
- **Primary completion:** 2024-03
- **Final completion:** 2024-04
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2023-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05597202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05597202, "Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05597202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*